Fig. 3From: High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective studyProportions of cases with overall survival (OS; A) and progression-free survival (PFS; B) < versus ≥ 6 months in patients with high versus low/no mutations in tumor and ctDNA at baselineBack to article page